Zai Lab (NASDAQ:ZLAB) CEO Ying Du Sells 24,543 Shares of Stock

Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) CEO Ying Du sold 24,543 shares of Zai Lab stock in a transaction that occurred on Friday, June 26th. The shares were sold at an average price of $17.46, for a total value of $428,520.78. Following the sale, the chief executive officer owned 1,192,840 shares in the company, valued at $20,826,986.40. This represents a 2.02% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Ying Du also recently made the following trade(s):

• On Thursday, May 14th, Ying Du sold 50,000 shares of Zai Lab stock. The stock was sold at an average price of $20.09, for a total value of $1,004,500.00.
• On Monday, April 6th, Ying Du sold 2,653 shares of Zai Lab stock. The shares were sold at an average price of $20.45, for a total transaction of $54,253.85.
• On Thursday, April 2nd, Ying Du sold 5,576 shares of Zai Lab stock. The shares were sold at an average price of $20.39, for a total value of $113,694.64.

Zai Lab Stock Performance

Shares of ZLAB stock traded up $0.41 during trading hours on Monday, reaching $18.41. The company had a trading volume of 944,868 shares, compared to its average volume of 821,367. The firm has a market cap of $2.09 billion, a PE ratio of -11.36 and a beta of 0.79. The business has a fifty day moving average price of $19.40 and a 200-day moving average price of $18.96. Zai Lab Limited Unsponsored ADR has a one year low of $15.96 and a one year high of $41.20.

Zai Lab (NASDAQ:ZLAB) last issued its earnings results on Wednesday, April 1st. The company reported ($0.50) earnings per share (EPS) for the quarter. Zai Lab had a negative return on equity of 24.32% and a negative net margin of 39.29%.The company had revenue of $99.61 million during the quarter. Equities research analysts forecast that Zai Lab Limited Unsponsored ADR will post -2.23 EPS for the current year.

Institutional Inflows and Outflows

A hedge fund recently raised its position in Zai Lab stock. SG Americas Securities LLC grew its holdings in Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) by 6.6% during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 10,396 shares of the company’s stock after acquiring an additional 642 shares during the period. SG Americas Securities LLC’s holdings in Zai Lab were worth $183,000 as of its most recent filing with the Securities & Exchange Commission. Institutional investors and hedge funds own 41.65% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts recently commented on ZLAB shares. JPMorgan Chase & Co. reduced their price objective on Zai Lab from $39.00 to $32.00 and set an “overweight” rating for the company in a research report on Wednesday, March 18th. Citigroup lowered their price objective on shares of Zai Lab from $47.00 to $44.00 and set a “buy” rating on the stock in a research note on Friday, May 8th. Weiss Ratings upgraded shares of Zai Lab from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Friday. Finally, Wall Street Zen cut shares of Zai Lab from a “hold” rating to a “sell” rating in a report on Saturday, May 16th. One equities research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat, Zai Lab currently has a consensus rating of “Moderate Buy” and an average target price of $45.83.

Zai Lab Company Profile

Zai Lab Ltd (NASDAQ: ZLAB) is a biopharmaceutical company focused on the research, development, manufacturing and commercialization of innovative therapies. Headquartered in Shanghai, China, Zai Lab operates R&D centers in Asia and the United States and maintains commercial offices across Greater China, North America, Europe and Australia. The company’s end-to-end platform encompasses discovery biology, translational development, clinical research and global supply chain management.

The company’s marketed portfolio is anchored by Brukinsa (zanubrutinib), a next-generation Bruton’s tyrosine kinase inhibitor approved for several B-cell malignancies.